Comparison of biomarkers levels in PsA cases vs PsC.
| Domain | Biomarker | Reference | PsA vs PsC | Sample HC,Size, PsA, PsC | OR | 95% CI | p | Mean Serum Concentration | Units for Serum Concentration |
|---|---|---|---|---|---|---|---|---|---|
| Bone resorption markers | |||||||||
| MMP-3 | |||||||||
| Chandran 2010 | Higher | 26, 26, 26 | 1.275 | 1.018–1.597 | 0.03 | 25.8 vs. 11.3 | ng/ml | ||
| Shibata 2009 | Higher | 11, 16, 15 | 6.3 | 1.3–37.8 | < 0.01 | OR of levels above cutoff | ng/ml | ||
| DKK-1 | |||||||||
| Dalbeth 2010 | Higher | 12, 38, 10 | < 0.001 | Charted | pg/ml | ||||
| Dalbeth 2010 | Higher (in erosive) | 12, 38, 10 | < 0.001 | Charted | pg/ml | ||||
| Dalbeth 2010 | Higher (in non-erosive) | 12, 38, 10 | < 0.05 | Charted | pg/ml | ||||
| RANKL | |||||||||
| Chandran 2010 | Equal | 26, 26, 26 | 0.999 | 0.994–1.004 | 0.77 | 319.8 vs 319.8 | pg/l | ||
| Dalbeth 2010 | Equal | 12, 38, 10 | > 0.05 | Charted | pmol/l | ||||
| Dalbeth 2010 | Equal (if erosive) | 12, 38, 10 | > 0.05 | Charted | pmol/l | ||||
| Dalbeth 2010 | Equal (if non-erosive) | 12, 38, 10 | > 0.05 | Charted | pmol/l | ||||
| M-CSF | Dalbeth 2010 | Higher | 12, 38, 10 | < 0.01 | Charted | pg/ml | |||
| Dalbeth 2010 | Higher (erosive) | 12, 38, 10 | < 0.001 | Charted | pg/ml | ||||
| Dalbeth 2010 | Equal (non-erosive) | 12, 38, 10 | > 0.05 | Charted | pg/ml | ||||
| Bone formation marker | |||||||||
| OPG | |||||||||
| Chandran 2010 | Higher | 26, 26, 26 | 1.011 | 1.002–1.021 | 0.02 | 663.8 vs 595.5 | pg/ml | ||
| Dalbeth 2010 | Equal | 12, 38, 10 | > 0.05 | Charted | pg/ml | ||||
| Dalbeth 2010 | Equal (if erosive) | 12, 38, 10 | > 0.05 | Charted | pg/ml | ||||
| Dalbeth 2010 | Equal (if non-erosive) | 12, 38, 10 | > 0.05 | Charted | pg/ml | ||||
| OC | Franck 2000 | Lower (in females) | 50, 32, 17 | < 0.05 | 2.28 vs 3.0 | ng/ml | |||
| Cartilage turnover marker | |||||||||
| COMP | Chandran 2010 | Equal | 26, 26, 26 | 1.000 | 0.999–1.001 | 0.35 | 2325.1 vs 2516.5 | ng/ml | |
| C1-2C | Chandran 2010 | Equal | 26, 26, 26 | 0.021 | < 0.001–16.442 | 0.26 | 0.6 vs 0.5 | mcg/ml | |
| CPII:C2C | Chandran 2010 | Higher | 26, 26, 26 | 4.762 | 1.352–16.767 | 0.02 | 4.76 vs 3.28 | No units (ratio) | |
PsA: psoriatic arthritis; PsC: cutaneous psoriasis without arthritis; HC: healthy control; MMP-3: matrix metalloproteinase-3; DKK-1: Dickkopf-1; RANKL: receptor activator of nuclear factor-κB ligand; M-CSF: macrophage colony-stimulating factor; OPG: osteoprotegerin; OC: osteocalcin; COMP: cartilage oligomeric matrix protein; C1-2C: a neoepitope released when type 2 cartilage is degraded by collagenases; CPII:C2C: ratio of cartilage degradation vs byproduct formation.